Efficacy and safety of decitabine combined with HAAG (homoharringtonine, aclarubicin, low-dose cytarabine and G-CSF) for newly diagnosed acute myeloid leukemia

The 7 + 3 regimen is the front-line induction chemotherapy in patients with newly diagnosed acute myeloid leukemia, with a response rate of 60-80%. But it’s not suitable for all patients especially old/unfit patients because of a higher treatment related toxicity. Therefore, safer and more effective...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Jun-Feng, Dai, Hai-Ping, Zhang, Qian-Qian, Yin, Jia, Li, Zheng, Cui, Qin-Ya, Tian, Xiao-Peng, Liu, Si-Ning, Jin, Zheng-Ming, Zhu, Xia-Ming, Wu, De-Pei, Tang, Xiao-Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605800/
https://www.ncbi.nlm.nih.gov/pubmed/36313659
http://dx.doi.org/10.3389/fonc.2022.998884

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605800/
https://www.ncbi.nlm.nih.gov/pubmed/36313659
http://dx.doi.org/10.3389/fonc.2022.998884

Ejemplares similares